Target intelligence / Profile preview

Voltage-dependent anion-selective channel protein 1 mRNA (VDAC1 mRNA)

Target
VDAC1 mRNA
Molecular classification
Messenger RNA, Nucleic acid
01

Overview

Voltage-dependent anion-selective channel protein 1 (VDAC1) mRNA is the transcript responsible for the synthesis of the VDAC1 protein, the most abundant porin in the outer mitochondrial membrane (UniProt P21796). This protein acts as a primary gatekeeper for the flux of ions and metabolites, such as ATP and calcium, between the mitochondria and the cytosol, thereby playing a central role in cellular energy metabolism and apoptosis (Shoshan-Barmatz et al., 2017). In many cancers, VDAC1 mRNA is significantly upregulated to support the high metabolic demands of rapidly proliferating cells and to inhibit mitochondrial-mediated cell death (PubMed: 28105114). Therapeutic strategies targeting VDAC1 mRNA involve the use of small interfering RNAs (siRNAs) or antisense oligonucleotides (ASOs) to silence the gene and deplete the VDAC1 protein (NIH: Gene ID 7416). This depletion leads to a collapse in mitochondrial function, a decrease in ATP production, and the induction of apoptosis in tumor cells. While promising, the development of these therapies faces challenges such as ensuring efficient delivery to target tissues and minimizing off-target effects that could impair mitochondrial function in healthy cells.

Other names
VDAC-1 mRNAMitochondrial porin 1 mRNAPorin 31HL mRNAPlasmalemmal porin mRNA
02

Mechanism of action

Gene silencing via RNA interference (RNAi) or antisense-mediated mRNA degradation, which reduces the translation of VDAC1 protein, leading to impaired mitochondrial metabolite exchange and induction of apoptosis.

03

Biological functions

Translation template for VDAC1 proteinRegulation of mitochondrial metabolismApoptosis regulationIon transport regulation
04

Disease associations

CancerNeurodegenerative diseaseCardiovascular diseaseType 2 diabetes
05

Safety considerations

Off-target effects of nucleic acid therapeuticsDelivery to specific target tissues (e.g., crossing the blood-brain barrier)Potential systemic mitochondrial toxicity in healthy tissuesImmune response to synthetic RNA/DNA
06

Interacting drugs

si-VDAC1 (Experimental siRNA)

1 more in the full profile.

07

Biomarkers

VDAC1 mRNA expression levelsVDAC1 protein levelsMitochondrial membrane potentialATP production levels

Beyond the preview

Go deeper on Voltage-dependent anion-selective channel protein 1 mRNA (VDAC1 mRNA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Voltage-dependent anion-selective channel protein 1 mRNA (VDAC1 mRNA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call